EGFR and non-small cell lung carcinoma: Mechanistic investigations further revealed that the positive feedback loop within the FGFR1-driven PLK1/STAT3 signaling pathway serves as a critical regulatory node mediating acquired resistance to EGFR-TKI therapy in NSCLC.